Lamontagne D - Search Results

1

Seasonal congestive heart failure mortality and hospitalisation trends, Quebec 1990-1998.

Feldman DE, Platt R, Déry V, Kapetanakis C, Lamontagne D, Ducharme A, Giannetti N, Frenette M, Beck EJ. Feldman DE, et al. Among authors: lamontagne d. J Epidemiol Community Health. 2004 Feb;58(2):129-30. doi: 10.1136/jech.58.2.129. J Epidemiol Community Health. 2004. PMID: 14729893 Free PMC article.

2

Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.

Bodart V, Bouchard JF, McNicoll N, Escher E, Carrière P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H. Bodart V, et al. Among authors: lamontagne d. Circ Res. 1999 Oct 29;85(9):796-802. doi: 10.1161/01.res.85.9.796. Circ Res. 1999. PMID: 10532947

3

Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension.

Millette E, Demeilliers B, Wu R, Laplante MA, El Midaoui A, Moreau P, Lamontagne D, de Champlain J. Millette E, et al. Among authors: lamontagne d. J Hypertens. 2003 Jan;21(1):125-35. doi: 10.1097/00004872-200301000-00022. J Hypertens. 2003. PMID: 12544444

4

The metabolism of bradykinin: a cornerstone for the understanding of the cardiovascular effects of metallopeptidase inhibitors.

Adam A, Dumoulin MJ, Lamontagne D. Adam A, et al. Among authors: lamontagne d. Can J Cardiol. 2001 May;17 Suppl A:11A-4A. Can J Cardiol. 2001. PMID: 11381288 Review.

5

Epinephrine release from the heart during left stellate ganglion stimulation in dogs.

Péronnet F, Nadeau R, Boudreau G, Cardinal R, Lamontagne D, Yamaguchi N, De Champlain J. Péronnet F, et al. Among authors: lamontagne d. Am J Physiol. 1988 Apr;254(4 Pt 2):R659-62. doi: 10.1152/ajpregu.1988.254.4.R659. Am J Physiol. 1988. PMID: 3354715

6

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.

Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. Bodart V, et al. Among authors: lamontagne d. Circ Res. 2002 May 3;90(8):844-9. doi: 10.1161/01.res.0000016164.02525.b4. Circ Res. 2002. PMID: 11988484

7

Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies.

Marleau S, Mulumba M, Lamontagne D, Ong H. Marleau S, et al. Among authors: lamontagne d. Cardiovasc Res. 2006 Jan;69(1):26-35. doi: 10.1016/j.cardiores.2005.08.022. Epub 2005 Oct 10. Cardiovasc Res. 2006. PMID: 16219302 Review.

8

Signaling pathways involved in the cardioprotective effects of cannabinoids.

Lépicier P, Bibeau-Poirier A, Lagneux C, Servant MJ, Lamontagne D. Lépicier P, et al. Among authors: lamontagne d. J Pharmacol Sci. 2006 Oct;102(2):155-66. doi: 10.1254/jphs.crj06011x. Epub 2006 Oct 7. J Pharmacol Sci. 2006. PMID: 17031075 Free article. Review.

9

The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.

Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N, Lamontagne D. Dumoulin MJ, et al. Among authors: lamontagne d. Can J Physiol Pharmacol. 2005 Feb;83(2):166-73. doi: 10.1139/y04-134. Can J Physiol Pharmacol. 2005. PMID: 15791290

10

Protection afforded by preconditioning to the diabetic heart against ischaemic injury.

Bouchard JF, Lamontagne D. Bouchard JF, et al. Among authors: lamontagne d. Cardiovasc Res. 1998 Jan;37(1):82-90. doi: 10.1016/s0008-6363(97)00234-4. Cardiovasc Res. 1998. PMID: 9539861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters